The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
The archive — 2025
Page 23 of 68 of this archive, newest first.
We split six vials four ways and posted them
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
What the trials counted as intolerance
An effect is dose-limiting when it prevents adequate intake, prevents normal activity, or produces a risk of its own. Discomfort alone is not the test.
STEP 2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Poland caps tirzepatide prescribing to 22 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What the new Australia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Xi'an: 15 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The shelf life ends when the diluent goes in
At low concentrations a measurable fraction of peptide can adsorb to glass and plastic surfaces, and the loss is largest exactly where it is least expected.
Retention time is not identity
Matching a retention time against a standard is evidence of consistency, not proof of identity. Two different species can elute at the same time on one method.
Homopeptide declines, for the 24th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
New Zealand health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A supplier suspends shipping to Japan after 5 consecutive customs detentions
The route did not close because of a rule about peptides.
The lowest effective dose is a real concept with almost no data behind it
What the labels permit, what clinicians do, and the size of the gap between them.
Discontinuation rates, read honestly
The ceiling varies severalfold between people, and nothing measurable at baseline predicts where it sits.
The supply gap as a clinical event
Why the reason for stopping changes what happens afterwards.
What changed at Homopeptide in September, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The 29-day notice: how a compounding wind-down works in Argentina
The document is four pages. Three of them are about dates.
What the orforglipron schedule assumes about a person it has never met
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
Turkey health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
From the floor in Chengdu: 22 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the new the United Kingdom guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Asparagine, glycine, and the two residues that decide a shelf life
We describe each pathway in enough chemical detail to explain why it is invisible to the method the trade uses, because that is the part which has practical consequences.
Why your endoscopist wants to know about your injection
This is the single interaction with ordinary medical care that patients most need to disclose, and it is the one most often not asked about.
New Zealand caps liraglutide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Halvard & Pike Apothecary of Portland, Maine enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Canada pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
SSA declines, for the 5th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.